Top-News
Werbung
Attraktive Knock-Outs auf Sanofi SA
Typ Hebel Bid / Ask WKN
Call
5,2 1,91 € / 1,93 €
SN5670
Typ Hebel Bid / Ask WKN
Put
5,1 1,95 € / 1,97 €
SN070Q
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA
Pharmazeutika Frankreich

Sanofi SA Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF
98,20 €
+0,87 €
+0,89%
21:22:59 Uhr
Depot/Watchlist
Aktienanzahl *
1,25 Mrd.
Marktkapitalisierung *
120,13 Mrd. €
Streubesitz
44,17%
Index-Zugehörigkeit
Euro Stoxx 50
IR-Website
zur Website
*Stand: 25.04.2025
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,79: ME6C98
Werbung

Ad-hocs

13.02.25 - GlobeNewswire
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn’t ...
07.02.25 - GlobeNewswire
Press Release: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 , Sanofi announced its intention to execute a share buyback program in ...
03.02.25 - GlobeNewswire
Press Release: Sanofi announces buy back of shares from L’Oréal
Sanofi announces buy back of shares from L’Oréal
31.01.25 - GlobeNewswire
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
30.01.25 - GlobeNewswire
Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025
22.01.25 - GlobeNewswire
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-​of-care VRd to treat transplant-​ineligible newly diagnosed multiple myeloma Approval is ...
21.01.25 - GlobeNewswire
Press Release: Opella reaches study milestone for Cialis
Opella reaches study milestone for Cialis
13.01.25 - GlobeNewswire
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
09.01.25 - GlobeNewswire
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-​primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R ...
23.12.24 - GlobeNewswire
Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-​generation pneumococcal conjugate vaccines Pneumococcal disease remains a ...
19.12.24 - GlobeNewswire
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors
17.12.24 - GlobeNewswire
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Duvakitug positive phase 2b results demonstrate best-​in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s ...
17.12.24 - GlobeNewswire
Press Release: Availability of the Q4 2024 Aide-mémoire
Availability of the Q4 2024 Aide-mémoire
13.12.24 - GlobeNewswire
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-​relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES ...
11.12.24 - GlobeNewswire
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
09.12.24 - GlobeNewswire
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
07.12.24 - GlobeNewswire
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
06.12.24 - GlobeNewswire
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024 . Following the press release on October 21, 2024 and the plan to ...
15.11.24 - GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch ...
14.11.24 - GlobeNewswire
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-​ineligible newly diagnosed multiple myeloma

Newssuche

Videos

newspaper
30.04.25 +22,47%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »